Eli Lilly is ready to soar with their latest results get ready for Triple Action GLP's

Retatrutide has shown amazing promises early on then with the grey market its been showing amazing results and now that they are coming out with trial 3 results and it looks even more promising they are ready to ignite that rocket fuel. They hit it out of the park with Tirzepatide, Novo has no real good answer their latest clinical results for their pipeline Zenagamtide hasn't shown much promise to get past Tirzepatide and far beind Reatrutide. Get ready for Eli to own the market outright with this drug. They are not only testing it for just obesity, but sleep apnea (from obesity), joint pain specfically knee pain, and are even going further with potential diabetes applications. [https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-drove-substantial-improvements) Todays announcement which has been anticipated and bought a ton of their stock, lets see what happens come monday! Also Eli Lilly has made a good oral GLP Foundayo, which seems to be great so far with those who don't want to inject or have terrible side effects from injecting. So a double win. Lets go Eli Lilly! Edit: Novo has released as mentioned above another GLP drug that acts on a different pathway: [https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html](https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html) Who knows who is going to make a GLP-4 which goes after all 4 mechanism mentioned.